Emeryville, United States
Kyverna Therapeutics, founded in 2018, is a United States-based clinical-stage biopharmaceutical company that aims to revolutionize treatment for autoimmune diseases by leveraging cell therapy. Their slogan, "Harnessing the power of cell therapy in autoimmune disease," highlights their focus on providing transformative therapies.
Their lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), a CD19-targeting CAR T-cell therapy, shows promise in altering the treatment landscape for B-cell-driven autoimmune diseases. With a completed registrational trial for stiff person syndrome and an ongoing trial for generalized myasthenia gravis, Kyverna is positioned at the forefront of neuroimmunology.
Recently backed by a Post Ipo Debt investment from Oxford Finance on 01 October 2025, Kyverna is capitalizing on its current successes to expand its pipeline, which includes next-generation therapies designed to enhance patient access and improve treatment experiences.
Zenas BioPharma
